Want to see AU:IVX full AI Analyst Report?
Top Page
Invion
(Sydney:IVX)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.04
▼(-12.50% Downside)
Action:Reiterated
Date:10/22/26
The score is driven primarily by weak financial performance: sustained losses, unstable revenues, and ongoing cash burn alongside a sharp erosion in equity. Technicals add further pressure with the price below all key moving averages and negative MACD momentum. Valuation is constrained by unprofitability (negative P/E) and the lack of a dividend yield.
Positive Factors
Proprietary cancer therapy platform
A proprietary light-activated therapy platform gives Invion a defined technological base rather than a broad, undifferentiated research strategy. If development continues to show efficacy, the platform could support multiple cancer applications and create longer-term partnering or commercialization opportunities.
Negative Factors
Persistent unprofitability
Persistent operating and net losses show that the current business has not yet converted its research activity into a profitable earnings base. Continued losses can consume capital, restrict investment choices, and make future growth dependent on improving economics or obtaining additional funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary cancer therapy platform
A proprietary light-activated therapy platform gives Invion a defined technological base rather than a broad, undifferentiated research strategy. If development continues to show efficacy, the platform could support multiple cancer applications and create longer-term partnering or commercialization opportunities.
Read all positive factors
Invion (IVX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$3.76M
Dividend YieldN/A
Average Volume (3M)86.52K
Price to Earnings (P/E)―
Beta (1Y)-0.41
Revenue GrowthN/A
EPS Growth48.77%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.06
Shares Outstanding110,553,130
10 Day Avg. Volume120,520
30 Day Avg. Volume86,515
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.59
Price to Sales (P/S)8.17
P/FCF Ratio-1.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Invion Business Overview & Revenue Model
Company Description
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent be...
Invion Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
47
Neutral
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 385.32K | 0.00 | 3.69M | 4.10M | 3.29M |
| Gross Profit | 385.32K | -1.29M | 1.00M | 1.21M | 969.12K |
| EBITDA | -3.94M | -4.00M | -4.57M | -965.37K | -1.82M |
| Net Income | -5.63M | -8.81M | -5.63M | -1.61M | -2.24M |
Balance Sheet | |||||
| Total Assets | 8.17M | 9.49M | 15.45M | 19.05M | 20.04M |
| Cash, Cash Equivalents and Short-Term Investments | 592.31K | 850.37K | 783.53K | 4.08M | 8.47M |
| Total Debt | 1.55M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.85M | 1.24M | 1.01M | 650.63K | 462.41K |
| Stockholders Equity | 5.32M | 8.25M | 14.44M | 18.40M | 19.58M |
Cash Flow | |||||
| Free Cash Flow | -2.38M | -2.97M | -3.30M | -4.39M | -8.36M |
| Operating Cash Flow | -2.37M | -2.97M | -2.40M | -1.81M | -1.11M |
| Investing Cash Flow | -68.83K | 0.00 | -900.00K | -2.58M | -7.25M |
| Financing Cash Flow | 2.18M | 3.04M | 0.00 | 15.80M | 15.80M |
Invion Technical Analysis
Negative
0.04
Price Trends
0.04
Negative
0.04
Negative
0.05
Negative
Market Momentum
>-0.01
Negative
49.40
Neutral
62.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IVX, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.40 is Neutral, neither overbought nor oversold. The STOCH value of 62.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IVX.
Invion Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$41.12M | 65.18 | 1.13% | 0.49% | 8.99% | 450.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$5.95M | -0.73 | -65.33% | ― | ― | 72.60% | |
44 Neutral | AU$18.20M | -6.88 | -13.81% | 6.27% | 5.93% | 66.32% | |
41 Neutral | AU$3.76M | -0.54 | -102.18% | ― | ― | 48.77% | |
40 Underperform | AU$2.95M | -0.23 | 102.60% | ― | 17.56% | 75.11% | |
39 Underperform | AU$21.43M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
* Healthcare Sector Average
AU:IVX
Invion
0.03
-0.06
-63.44%
AU:PER
Percheron Therapeutics
―
―
―
AU:RGT
Argent Biopharma
0.03
-0.05
-66.67%
AU:MVP
Medical Developments International Limited
0.37
-0.33
-47.86%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-20.00%
AU:IDT
IDT Australia Limited
0.04
-0.02
-26.67%
Invion Corporate Events
Invion secures major funding as Photosoft cancer trial advances to Phase II
Oct 28, 2026
Invion has completed patient treatment and closed recruitment for its Phase I non-melanoma skin cancer trial using its Photosoft platform, with preliminary data from 14 patients showing no treatment-related adverse events or dose-limiting toxiciti...
Invion Moves to Fully Virtual AGM and Paperless Meeting Materials
Oct 23, 2026
Invion Limited has scheduled its Annual General Meeting of shareholders to be held virtually on 25 November 2026 at 1:00pm AEDT, using online webinar technology that allows investors to attend remotely, ask questions and vote in real time. Shareho...
Invion Plans New Share and Option Issue in ASX Placement
Oct 21, 2026
Invion Limited has lodged a notice with the ASX outlining a proposed issue of new securities via a placement or similar capital-raising mechanism. The company plans to issue up to 1,374,003 ordinary fully paid shares under code IVX and 11,055,313 ...
Invion secures financing to cover up to 85% of clinical trial costs
Oct 20, 2026
Invion has secured two complementary financing arrangements that are expected to cover up to about 85% of its current and future clinical trial costs, including ongoing non-melanoma skin cancer and upcoming anogenital cancer trials. The structure ...
Invion and Percheron Align on Novel Cancer Combination Using Photosoft and VISTA Immunotherapy
Oct 19, 2026
Invion has entered a non-exclusive preclinical research collaboration with fellow ASX-listed biotech Percheron Therapeutics to assess the combination of Percheron’s anti-VISTA monoclonal antibody HMBD-002 and Invion’s Photosoft INV043 ...
Percheron and Invion pair VISTA immunotherapy with Photosoft cancer PDT
Oct 19, 2026
Percheron Therapeutics and Invion have entered a preclinical research collaboration to test Percheron’s anti-VISTA monoclonal antibody HMBD-002 with Invion’s Photosoft-based photodynamic therapy, INV043, in solid tumours. The partners ...
Invion Advances Photosoft-Based Skin Cancer Therapy After Strong Phase I Safety Readouts
Oct 19, 2026
Invion has closed patient recruitment and completed treatments in its Phase I non-melanoma skin cancer trial of investigational therapy INV043, reporting strong safety outcomes across 14 patients, including no serious adverse events, dose-limiting...
Invion Plans ASX Share Placement to Boost Capital
Sep 29, 2026
Invion Limited has notified the ASX of a proposed placement involving up to 8,218,000 ordinary fully paid shares. The new securities are expected to be issued on Dec. 4, 2026, and will be quoted on the ASX subject to compliance with listing rules....
Invion Secures $400,000 in Director Loans to Support Working Capital
Sep 29, 2026
Invion has secured short-term funding support from two board members through unsecured director loans totaling $400,000 to bolster working capital. Executive Chair and CEO Prof Thian Chew and Non-Executive Director Alan Yamashita have each committ...
Invion Sets Out 2026 Governance Framework and Board Changes
Aug 26, 2026
Invion has detailed its corporate governance practices for the financial year ended 30 June 2026, outlining the composition of its four-member Board and recent changes, including the resignation of a non-executive director and the appointment of P...
Invion Narrows Annual Loss but Net Tangible Assets Slide Deeper Into Negative Territory
Aug 26, 2026
Invion Limited reported revenue of $384,707 for the year ended 30 June 2026 and a reduced net loss of $5.63 million, down 36% from the prior year, with no dividends declared. Despite the improved bottom line, net tangible assets per share fell fur...
Invion Appoints New Director With No Current Securities Interests
Aug 20, 2026
Invion Limited has appointed Paul Hilton Field as a director effective 18 August 2026, according to an initial director’s interest notice lodged with the ASX. The filing confirms that Field currently holds no relevant interests in Invion sec...
Invion strengthens clinical leadership and expands Photosoft into new cancer and eye indications
Jul 31, 2026
Invion reported a modest improvement in quarterly cash reserves to $592,000, supported by expected RD tax incentive receipts and disciplined spending on research and corporate costs. The company also disclosed related‑party payments of $66,0...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.